Skip to main content
OpenTrials
Completed

NCT Number: NCT01844739

A Phase 1 Study Evaluating Safety and Tolerability of NVN1000 Gel

This is a 2 week Phase 1 study of SB204 (NVN1000 Gel) in healthy adult volunteers with elevated Propionibacterium acnes (P. acnes) counts. Subjects will apply NVN1000 4% Gel or Vehicle Gel twice daily to their face. Assessments will include cutaneous tolerability, safety, and P. acnes counts.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

KGL

Broomall, Pennsylvania, 19008, United States

About this study

In this single-center, vehicle gel-controlled, evaluator and subject blinded study, approximately 30 otherwise healthy adult subjects with elevated P. acnes counts will be randomized 2:1 to NVN1000 4% Gel or Vehicle Gel. The subjects will apply the test material twice daily to their face after washing. Subjects will be seen daily at the skin study center during the week and will apply their evening and weekend dose at home. Cutaneous tolerability will be assessed by the Investigator at Baseline, Week 1, and Week 2. Safety assessments include collection of adverse events, laboratory results, and clinically significant changes in physical examination. P. acnes counts will be obtained at Baseline, Week 1 and Week 2.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy adult male or female volunteers
  • If a woman of child-bearing potential, agrees to use effective method of birth control during the study and for 30 days after the final study visit
  • Agree to refrain from use of antimicrobial topical products during study

Exclusion criteria

  • Any skin disorders of acute or chronic nature including psoriasis, eczema, etc
  • Female subjects who are pregnant, nursing, or planning to become pregnant
  • Subjects who have used topical or systemic antibiotics, estrogens, drugs associated with methemoglobinemia, nitrate donors
  • Subjects with baseline methemoglobin > 2%
  • Subjects with clinically significant anemia

Treatment and study plan

NVN1000 4% Gel

Drug

Applied topically twice daily

Other names: SB204

Vehicle gel

Drug

Applied topically twice daily

Other names: Placebo

Primary outcomes

  1. Tolerability based on the cutaneous tolerability scores

    Time frame: 2 weeks

    Cutaneous tolerability assessments (erythema, scaling, dryness, pruritus, burning/stinging) will be summarized with frequency counts and percentages at each score category for Week 1 and Week 2.

Secondary outcomes

  1. Safety which includes reported adverse events, clinically significant changes in physical exam, and labs

    Time frame: 2 weeks

    Adverse events will be summarized by treatment group. Clinically significant changes in physical examination, including vital signs, over the treatment period will be reported as adverse events. Changes in laboratory results will be analyzed.

Other outcomes

  1. Change in P. acnes counts

    Time frame: 2 weeks

    P. acnes counts will be obtained by culture at Baseline, Week 1 and Week 2/end of treatment. The change in P. acnes counts over time will be analyzed.

Sponsors and collaborators

Lead sponsor

Novan, Inc.

Industry

Registry information

Official study title

A Phase 1, Multiple-dose, Evaluator-blind, Randomized, Parallel Group Study Evaluating the Safety and Cutaneous Tolerability of SB204 (NVN1000 Gel) in Healthy Volunteers

Important dates

Study start
2013
Primary completion
2013
Study completion
2013
First posted
May 1, 2013
Registry last updated
Nov 19, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.